Purple Biotech Ltd. (PPBT)

USD 3.61

(-7.91%)

Market Cap (In USD)

9.32 Million

Revenue (In USD)

-

Net Income (In USD)

-19.88 Million

Avg. Volume

21.94 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.0-20.6
PE
-
EPS
-
Beta Value
0.384
ISIN
US74638P1093
CUSIP
74638P109
CIK
1614744
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gil Efron CPA, M.A.
Employee Count
-
Website
https://purple-biotech.com
Ipo Date
2015-11-20
Details
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.